目的 研究英夫利西单抗治疗中重度斑块状银屑病患者生活质量的影响因素.方法 对31例中重度斑块状银屑病患者予以英夫利西单抗治疗,观察患者在治疗前,治疗后2、6、14周时的银屑病皮损面积和严重度指数(PASI)和皮肤病生活质量指数(DLQI)评分.结果 在英夫利西单抗治疗前,患者PASI评分为(18.48± 5.08)分,治疗14周后,患者PASI评分降为(3.03±2.65)分;皮肤病生活质量指数(DLQI)评分治疗前为(14.74± 4.67)分,治疗14周后降为(1.87±1.82)分,治疗前后差异有统计学意义(P＜0.05).通过对患者生活质量的相关因素:性别、年龄、文化程度、病程、PASI评分进行逐步多元线性回归分析, PASI评分和病程进入回归方程有统计学意义(P＜0.05).结论 中重度斑块状银屑病在英夫利西单抗治疗后,病情得到快速控制,低生活质量得以改善.PASI评分和病程是影响患者生活质量的主要因素,PASI评分越低,病程越短,中重度斑块状银屑病患者生活质量越好.%Objective To study the influence factors of quality of life in patients with moderate to severe plaque psoriasis treated by infliximab. Method A total of 31 patients with moderate to severe plaque psoriasis were observed. These patients were treated by infliximab. PASI and DLQI were measured before the intervention and 2, 6 and 14 weeks after the intervention. Results The mean PASI score at baseline was (18.48±5.08), after 14 weeks treatment, the mean PASI score changed to (3.03±2.65). DLQI score was (14.74± 4.67) at baseline, after 14 weeks treatment, the mean DLQI score changed to (1.87±1.82). For both the PASI score and the DLQI score, there were statistic difference between before and after treatment(P<0.05). DLQI had correlation with sex, age, degree of education, disease duration and PASI. Stepwise multiple linear regression analysis revealed that PASI and disease duration were predictors of DLQI(P<0.05). Conclusion Infliximab treatment can rapidly reduce the signs and symptoms of psoriasis and improve the lower quality of life in patients with moderate to severe plaque psoriasis. PASI and disease duration are significant predictors of DLQI. The lower PASI and shorter disease duration mean the better quality of life of the patients.
展开▼
